RxDoctor Payments Data

David Shaker, DO

Internal Medicine · Hackensack, NJNPI 1396130365

Payments from drug & device makers

$33,986in general payments, 2019–2025

Across 330 payments — averaging $102.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$29K
  • Novo Nordisk$1K
  • Abbott$876
  • Amgen$423
  • AstraZeneca$385
  • Medtronic$228
  • plus $2K from 40 others

What the payments were for

  • Speaking & faculty fees$27,30080%
  • Travel & lodging$6852%
  • Food & beverage$5,88417%
  • Education$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,986 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$203,007
Medicare patients
437
Services billed
2,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban187$93,175
XifaxanRifaximin33$84,277
MounjaroTirzepatide44$45,874
ProliaDenosumab19$32,559
JanuviaSitagliptin Phosphate25$25,538
FarxigaDapagliflozin Propanediol25$24,265
OzempicSemaglutide21$19,659
XareltoRivaroxaban28$15,321
JardianceEmpagliflozin13$10,609
EntrestoSacubitril/Valsartan21$9,939
Divalproex Sodium98$9,474
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,560
Daptomycin15$7,084
Atorvastatin Calcium500$6,562
Sucralfate64$4,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$93,175187 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$30$84,27733 claims
Lilly USA, LLCMounjaro$28,702$45,87444 claims
AmgenProlia$423$32,55919 claims
MerckJanuvia$25$25,53825 claims
AstraZenecaFarxiga$385$24,26525 claims
Novo NordiskOzempic$1,109$19,65921 claims
Johnson & JohnsonXarelto$121$15,32128 claims
Boehringer IngelheimJardiance$49$10,60913 claims
NovartisEntresto$104$9,93921 claims
GSKTrelegy Ellipta$172$8,56011 claims
AbbVieCombigan$184$2,67512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →